MD / MS / DNB · MD Respiratory Medicine

Pulmonary hypertension

Read the topic background here, then explore the labeled visual and structured learning explanations on this page.

Read explanation on this page ↓ See diagram ↓
Read here · Topic background

Pulmonary hypertension — on-site reading

An introductory overview for this topic. The article introduction is reproduced here, so you do not need to leave MedAtlas to read it. It may not match the latest official medical guidance.

Pulmonary hypertension (PH or PHTN) is a condition of increased blood pressure in the arteries of the lungs. Symptoms include shortness of breath, fainting, tiredness, chest pain, swelling of the legs, and a fast heartbeat. The condition may make it difficult to exercise. Onset is typically gradual.
According to the definition at the 6th World Symposium of Pulmonary Hypertension in 2018, a patient is deemed to have pulmonary hypertension if the pulmonary mean arterial pressure is greater than 20mmHg at rest, revised down from a purely arbitrary 25mmHg, and pulmonary vascular resistance (PVR) greater than 3 Wood units.
The cause is often unknown. Risk factors include a family history, prior pulmonary embolism (blood clots in the lungs), HIV/AIDS, sickle cell disease, cocaine use, chronic obstructive pulmonary disease, sleep apnea, living at high altitudes, and problems with the mitral valve. The underlying mechanism typically involves inflammation and subsequent remodeling of the arteries in the lungs. Diagnosis involves first ruling out other potential causes. High cardiac output states, such as advanced liver disease or the presence of large arteriovenous fistulas, may lead to an elevated mean pulmonary artery pressure (mPAP) greater than 20 mm Hg despite a pulmonary vascular resistance (PVR) less than 2 Wood units, which does not necessarily indicate pulmonary vascular disease.
As of 2022 there was no cure for pulmonary hypertension, although research to find a cure is ongoing. Treatment depends on the type of disease. A number of supportive measures such as oxygen therapy, diuretics, and medications to inhibit blood clotting may be used. Medications specifically used to treat pulmonary hypertension include epoprostenol, treprostinil, iloprost, bosentan, ambrisentan, macitentan, and sildenafil, tadalafil, selexipag, riociguat. Lung transplantation may be an option in severe cases.

The frequency of occurrence is estimated at 1,000 new cases per year in the United States. Females are more often affected than males. Onset is typically between 20 and 60 years of age. Pulmonary hypertension was identified by Ernst von Romberg in 1891.

How this connects to MD Respiratory Medicine

Cardiovascular function couples electrical activation, muscle contraction, chamber filling and vascular resistance to tissue perfusion. Structural, rhythm or vascular disorders can change symptoms and measurements in different ways; evaluation integrates hemodynamics, anatomy, time course and objective evidence.

Text credit: Wikipedia contributors, “Pulmonary hypertension”, original article · authors & revision history · CC BY-SA 4.0. Unmodified opening extract, accessed 24 September 2026. This Wikipedia-derived section is provided under CC BY-SA 4.0; the independent MedAtlas notes and design are separate works.

On-site diagram

Pulmonary hypertension · visual study map

Scalable vector illustration. Labeled conceptual map, not a precise anatomical, histological or diagnostic image.
TOPIC LEARNING MAP · NOT AN ANATOMICAL PLATE01 · BackgroundPulmonary hypertension (PH or PHTN) is acondition of increased blood pressure inthe arteries of the lungs.02 · Main conceptSymptoms include shortness of breath,fainting, tiredness, chest pain,swelling of the legs, and a fast…03 · Related processThe condition may make it difficult toexercise.04 · Study connectionAccording to the definition at the 6thWorld Symposium of PulmonaryHypertension in 2018, a patient is…Pulmonary hypertensionRead the full text below the visual · all reading is on this website

The wording in this learning map is adapted from the attributed Wikipedia background section below (CC BY-SA 4.0).

Study foundation 01

What the underlying subject studies

At postgraduate and higher-specialty level, begin with normal anatomy and physiology of the relevant organ system, then compare distinct disease mechanisms, their evidence base and the limitations of available investigations.

Study foundation 02

How mechanisms and evidence connect

Advanced study requires evidence appraisal, multidisciplinary interpretation and a clear distinction between established facts, hypotheses and research findings. Procedural, diagnostic and prescribing skills must be learned under an accredited program.

Study foundation 03

How to develop a sound explanation

Identify the scope of this topic within the named specialty, connect it to the applicable patient population and formulate a structured question that can be answered using current specialty literature and supervised teaching.

References and verification (optional)

All reading material on this page appears above. The links below are for checking the primary syllabus, research or source attribution, not requirements for opening this lesson.

NBEMS DNB broad-specialty curricula ↗

Find research on Pulmonary hypertension ↗